Most Read Articles
09 Jun 2020
Stenting cholesterol-blocked arteries in the brain appears to reduce recurrent stroke risk in patients with intracranial atherosclerotic disease (ICAD), one-year results of the WOVEN* trial, presented at the International Stroke Conference (ISC) 2020, have shown.
Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
4 days ago
Increased dietary intake of multiple nutrients, such as minerals, vitamins, and carotenoids, protects against the risk of progression to late age-related macular degeneration, specifically geographic atrophy, according to a study.
11 Aug 2020
In this final issue of our series, join us as we look into the upcoming results of the pivotal EMPEROR trials, which will investigate the use of empagliflozin in patients with either preserved or reduced ejection fraction heart failure, with or without type 2 diabetes. Understand why heart failure has such a high clinical burden, and the great unmet need in providing solutions for it.

Product Highlight - Saxenda

4 days ago

Active ingredient: 1 ml of solution contains 6 mg of liraglutide. One pre-filled pen contains 18 mg liraglutide in 3 mL

Indications:
Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of
≥30 kg/m² (obese), or
≥27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.

Dosage & Administration:
The starting dose is 0.6 mg daily. The dose should be increased to 3.0 mg daily in increments of 0.6 mg with at least one week interval to improve gastro-intestinal tolerability. Saxenda® is administered once daily at any time, independent of meals, subcutaneously injected in the abdomen, thigh or upper arm, preferably around the same time every day.


Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Thailand digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
09 Jun 2020
Stenting cholesterol-blocked arteries in the brain appears to reduce recurrent stroke risk in patients with intracranial atherosclerotic disease (ICAD), one-year results of the WOVEN* trial, presented at the International Stroke Conference (ISC) 2020, have shown.
Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
4 days ago
Increased dietary intake of multiple nutrients, such as minerals, vitamins, and carotenoids, protects against the risk of progression to late age-related macular degeneration, specifically geographic atrophy, according to a study.
11 Aug 2020
In this final issue of our series, join us as we look into the upcoming results of the pivotal EMPEROR trials, which will investigate the use of empagliflozin in patients with either preserved or reduced ejection fraction heart failure, with or without type 2 diabetes. Understand why heart failure has such a high clinical burden, and the great unmet need in providing solutions for it.